课题基金 / 基金详情

Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia

Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia
阴部神经调节治疗尿失禁和大便失禁以及括约肌协同失调
批准号:
10593689
负责人:
KARL B THOR
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-30 至 2024-08-31

项目摘要

项目成果

KARL B THOR的其他基金

相似基金

相关文献

中文摘要
翻译
总结/摘要 脊髓损伤(SCI)经常产生严重的,终身的膀胱和肠功能障碍,导致 尿失禁(UI)和大便失禁(FI)以及括约肌协同失调,导致尿潴留, 粪便嵌塞目前的尿失禁护理标准包括适度有效的药物,复杂的 手术或者成人尿布膀胱和肠道排尿需要每天多次膀胱导管插入术 以及对大多数SCI患者粪便的定期数字提取。尿布有异味,导尿管会导致 频繁的尿路感染和数字肠道计划既耗时又令人耻辱 个人和/或其护理人员。对于大多数SCI患者来说,膀胱和肠道功能障碍会影响他们的 职业和社会生活比他们不能走路。 我们在麻醉制剂中的第1阶段STTR应用确定了电脉冲特性 (e.g. 3 T,100 usec,10-30 Hz),当施加到阴部(PUD)神经时,刺激传出神经, 传入纤维分别产生尿道和肛门括约肌的持续收缩(>1小时) 以及抑制膀胱活动并增加膀胱容量。膀胱漏尿点压力也 明显增加。这些生理效应应显着降低UI和FI时,复制在 患者此外,还使用了用于刺激PUD神经的相同电极和刺激器。 能够通过从低频切换到kHz高频(恒定占空比)来阻断PUD神经 阻止括约肌收缩的脉冲。 在第二阶段SBIR应用的目标1中,首先测试慢性SCI制剂以确认它们 对上述脉搏特征的反应类似于我们在脊柱完整研究中的1期研究。对于目标2,a 进行转化研究,其中植入式脉冲发生器(IPG)与电极连接 双侧放置在慢性SCI制备物的阴部神经上2个月。在此期间,IPG 当需要“储存”尿液和粪便时,用于刺激PUD神经,然后切换到阻断 PUD神经时,“排尿”的尿液和粪便是期望的。IPG使用遥控器在 存储模式和清空模式。控制UI和FI发作的有效性通过比较 测试日发作的次数和体积/重量,有与没有激活存储模式。 通过测量药物诱导的排尿效率来评估控制括约肌协同失调的有效性 以及在测试日对信用点难度的主观评级,有与没有激活排泄模式。在 研究结束时,评估括约肌的括约肌肥大和疲劳增加的迹象。 抵抗力强的肌肉纤维最后,为了准备FDA的讨论,我们将评估不同的制剂, 考虑GLP安全性研究。
英文摘要
SUMMARY / ABSTRACT Spinal cord injury (SCI) frequently produces severe, life-long bladder and bowel dysfunction that results in urinary (UI) and fecal incontinence (FI), as well as sphincter dyssynergia that results in urinary retention and fecal impaction. Current standard of care for incontinence consists of modestly effective drugs, complicated surgery, or adult diapers. Bladder and bowel voiding require multiple-times-daily catheterization of the bladder and regular digital extraction of feces for most SCI individuals. Diapers are odiferous, catheters induce frequent urinary tract infections, and digital bowel programs are time-consuming and stigmatizing for the individual and/or their caregiver. For most people with SCI, bladder and bowel dysfunction impacts their professional and social lives more than their inability to walk. Our Phase 1 STTR application, in anesthetized preparations, determined electrical pulse characteristics (e.g. 3T, 100 usec, 10-30 Hz), which when applied to the pudendal (PUD) nerve, stimulated efferent and afferent fibers to produce, respectively, sustained contractions (>1 hour) of the urethral and anal sphincters and inhibition of bladder activity with increased bladder capacity. Bladder leak point pressures were also markedly increased. These physiological effects should significantly reduce UI and FI when replicated in patients. In addition, the same electrodes and stimulator that were used to stimulate the PUD nerve were also able to block the PUD nerve by switching from low frequency to kHz high frequency (constant duty cycle) pulses that prevented sphincter contractions. In Aim 1 of this Phase 2 SBIR application, chronic SCI preparations are first tested to confirm that they respond to the above pulse characteristics similarly to our Phase 1 study in spinal intact studies. For Aim 2, a translational study is performed in which an implantable pulse generator (IPG), is interfaced with electrodes placed bilaterally on the pudendal nerves of chronic SCI preparations for 2 months. During this time, the IPG is used to stimulate the PUD nerve when “Storage” of urine and feces is desired and then switched to block the PUD nerve when “Voiding” of urine and feces is desired. The IPG uses a remote control to switch between Storage Mode and Voiding Mode. Effectiveness in controlling UI and FI episodes is assessed by comparing the number and volume/weight of episodes on test days, with versus without, activation of Storage Mode. Effectiveness for controlling sphincter dyssynergia is assessed by measuring drug-induced voiding efficiency and subjective ratings of Credé difficulty on test days, with versus without, activation of Voiding Mode. At the end of the study sphincters are evaluated for signs of sphincter muscle hypertrophy and increases in fatigue- resistant muscle fibers. Finally, in preparation for FDA discussions, we will assess different preparations in consideration of GLP safety studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia
  • 批准号:
    10267726
  • 项目类别:
  • 资助金额:
    $43.14万
  • 财政年份:
    2019
  • 负责人:
    KARL B THOR
  • 依托单位:
Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury
  • 批准号:
    9900511
  • 项目类别:
  • 资助金额:
    $26.94万
  • 财政年份:
    2019
  • 负责人:
    KARL B THOR
  • 依托单位:
Development of a first-in-class therapeutic for producing 'on-demand' voiding
  • 批准号:
    9344769
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2017
  • 负责人:
    KARL B THOR
  • 依托单位:
An optimized NK2R agonist for 'on-demand' voiding
  • 批准号:
    9464120
  • 项目类别:
  • 资助金额:
    $115.82万
  • 财政年份:
    2016
  • 负责人:
    KARL B THOR
  • 依托单位:
海外基金